OncoSec Medical Inc (ONCSQ)

[Waitforit53]

From the "Corporate Milestones of 2017"

Finalize drug supply partnership for ImmunoPulse® IL-12 registration-directed trial

Initiation of registration-directed trial in stage III/IV melanoma anti-PD-1 non-responder population

Data announcement at key scientific meeting from ongoing clinical program in predicted anti-PD-1 non-responder population in advanced melanoma

Announcement of key collaborations and technology access program using TRACE™- enabled delivery technology

IND preparation for first-in-human studies for the next clinical candidate in 2018

Secure licensing or commercial partnership(s)

My take is they could parcel out the Melanoma combo program for non-responders. But whether the IND is picked up as well will probably be negotiable in the deal. Punit has always tried to position the company to go it alone so they always can move forward with their science. They have Australia set up as a go-it-alone option, but also expressed the desire for a "global" registration trial and the wish to partner with one of only two PD-1 drug companies that meet those requirments--Merck's Ketruda and BMS's Yervoy. Of coarse Merck would be preferred but obviously no deal yet.

I'm also curious as to how they farm out the IL-12 melanoma platform for just Melanoma, when the IL-12 + Combo platform, has potential across all indications, with even greater accuracy with TRACE. I think the Monetizing of TRACE will help calculations of ImmunnoPulse treatment cost per patient and over-all valuation of company in estimating platform/company exit opportunity valuation.